{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:00:29Z","timestamp":1781193629873,"version":"3.54.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clinthera.2026.05.021","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:59:10Z","timestamp":1779911950000},"page":"565-570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advancements in Prenatal Diagnosis and Potential Fetal Therapies for Spinal Muscular Atrophy"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8881-9138","authenticated-orcid":false,"given":"Marie-Julie","family":"Trahan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Arditi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Baptiste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.05.021_bib0001","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/GRF.0000000000000654","article-title":"Spinal muscular atrophy: a potential target for in utero therapy","volume":"64","author":"Baptiste","year":"2021","journal-title":"Clin Obs Gynecol"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JND-190424","article-title":"Advances in treatment of spinal muscular atrophy - new phenotypes, new challenges, new implications for care","volume":"7","author":"Schorling","year":"2020","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0003","unstructured":"Prior TW LM, Finanger EL. Spinal muscular atrophy: gene reviews; 2000. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1352\/. Accessed 26 March, 2026."},{"key":"10.1016\/j.clinthera.2026.05.021_bib0004","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0005","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1097\/AOG.0000000000001951","article-title":"Committee Opinion No. 690: carrier screening in the age of genomic medicine","volume":"129","year":"2017","journal-title":"Obs Gynecol"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0006","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1542\/gr.52-3-32","article-title":"Impact of newborn screening for spinal muscular atrophy","volume":"52","year":"2024","journal-title":"AAP Gd Rounds"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0007","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2147\/TCRM.S172291","article-title":"Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives","volume":"15","author":"Dangouloff","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0008","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1126\/scitranslmed.abb6871","article-title":"Impaired prenatal motor axon development necessitates early therapeutic intervention in severe SMA","volume":"13","author":"Kong","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0009","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/ana.410420314","article-title":"Congenital axonal neuropathy caused by deletions in the spinal muscular atrophy region","volume":"42","author":"Korinthenberg","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0010","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2217\/fnl.13.58","article-title":"Neurodegeneration in spinal muscular atrophy: from disease phenotype and animal models to therapeutic strategies and beyond","volume":"9","author":"Monani","year":"2014","journal-title":"Future Neurol"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0011","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/biomedicines13081796","article-title":"Prenatal management of spinal muscular atrophy in the era of genetic screening and emerging opportunities in in utero therapy","volume":"13","author":"Me\u017enari\u0107","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0012","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1093\/brain\/awaf123","article-title":"In utero therapy for spinal muscular atrophy: closer to clinical translation","volume":"148","author":"Tizzano","year":"2025","journal-title":"Brain"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0013","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1002\/pd.6228","article-title":"Investigating attitudes toward prenatal diagnosis and fetal therapy for spinal muscular atrophy","volume":"42","author":"Schwab","year":"2022","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0014","doi-asserted-by":"crossref","first-page":"eadv4656","DOI":"10.1126\/scitranslmed.adv4656","article-title":"Intra-amniotic antisense oligonucleotide treatment improves phenotypes in preclinical models of spinal muscular atrophy","volume":"17","author":"Borges","year":"2025","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0015","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1056\/NEJMc2300802","article-title":"Risdiplam for prenatal therapy of spinal muscular atrophy","volume":"392","author":"Finkel","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0016","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1056\/NEJMoa2410120","article-title":"Further comments on risdiplam for prenatal therapy of spinal muscular atrophy. Reply","volume":"393","author":"Finkel","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0017","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1056\/NEJMc2504911","article-title":"Further comments on risdiplam for prenatal therapy of spinal muscular atrophy","volume":"393","author":"Wadman","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0018","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1056\/NEJMc2504911","article-title":"Further comments on risdiplam for prenatal therapy of spinal muscular atrophy","volume":"393","author":"Yeo","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2024.06.025","article-title":"Amniocentesis in pregnancies at or beyond 24 weeks: an international multicenter study","volume":"232","author":"Zemet","year":"2025","journal-title":"Am J Obs Gynecol"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0020","unstructured":"BillionToOne Ub. Spinal muscular atrophy 2024. Available from: https:\/\/www.unityscreen.com\/conditions\/spinal-muscular-atrophy. Accessed 26 March, 2026."},{"key":"10.1016\/j.clinthera.2026.05.021_bib0021","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/ejhg.2016.195","article-title":"Non-invasive prenatal diagnosis of spinal muscular atrophy by relative haplotype dosage","volume":"25","author":"Parks","year":"2017","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0022","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/uog.15947","article-title":"Targeted sequencing of maternal plasma for haplotype-based non-invasive prenatal testing of spinal muscular atrophy","volume":"49","author":"Chen","year":"2017","journal-title":"Ultrasound Obs Gynecol"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0023","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/acn3.779","article-title":"Neurofilament as a potential biomarker for spinal muscular atrophy","volume":"6","author":"Darras","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0024","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/mus.27187","article-title":"Safety and efficacy of nusinersen in spinal muscular atrophy: the EMBRACE study","volume":"63","author":"Acsadi","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0025","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0026","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0027","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.27853","article-title":"Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study","volume":"68","author":"Crawford","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0028","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0029","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0030","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2019.08.017","article-title":"Fetal gene therapy using a single injection of recombinant AAV9 rescued SMA phenotype in mice","volume":"27","author":"Rashnonejad","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0031","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1016\/j.ymthe.2025.06.012","article-title":"In utero genetic therapy: treatment of early onset neurological disorders before they start","volume":"33","author":"Borges","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101263","article-title":"Prenatal AAV9-GFP administration in fetal lambs results in transduction of female germ cells and maternal exposure to virus","volume":"32","author":"Borges","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0033","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1056\/NEJMoa2410120","article-title":"Risdiplam in presymptomatic spinal muscular atrophy","volume":"393","author":"Finkel","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0034","doi-asserted-by":"crossref","first-page":"B9","DOI":"10.1016\/j.ajog.2021.09.001","article-title":"Society for maternal-fetal medicine special statement: beyond the scalpel: in utero fetal gene therapy and curative medicine","volume":"225","author":"Shanahan","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0035","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1097\/AOG.0000000000001150","article-title":"ACOG Committee Opinion No. 646: ethical considerations for including women as research participants","volume":"126","year":"2015","journal-title":"Obs Gynecol"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0036","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/jgc4.1549","article-title":"Evolving approaches to prenatal genetic counseling for spinal muscular atrophy in the new treatment era","volume":"31","author":"Zettler","year":"2022","journal-title":"J Genet Couns"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0037","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/bcp.16267","article-title":"A systematic review of economic evaluations of orphan medicines for the management of spinal muscular atrophy","volume":"91","author":"Belan\u010di\u0107","year":"2025","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0038","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s10815-023-02738-7","article-title":"Cost-effectiveness of IVF with PGT-M\/A to prevent transmission of spinal muscular atrophy in offspring of carrier couples","volume":"40","author":"Khorshid","year":"2023","journal-title":"J Assist Reprod Genet"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0039","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/genes14071403","article-title":"The carrier frequency of two SMN1 genes in parents of symptomatic children with SMA and the significance of SMN1 exon 8 in carriers","volume":"14","author":"Davidson","year":"2023","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0040","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/gim.2013.84","article-title":"An Ashkenazi Jewish SMN1 haplotype specific to duplication alleles improves pan-ethnic carrier screening for spinal muscular atrophy","volume":"16","author":"Luo","year":"2014","journal-title":"Genet Med"},{"key":"10.1016\/j.clinthera.2026.05.021_bib0041","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/gim.2016.215","article-title":"The next generation of population-based spinal muscular atrophy carrier screening: comprehensive pan-ethnic SMN1 copy-number and sequence variant analysis by massively parallel sequencing","volume":"19","author":"Feng","year":"2017","journal-title":"Genet Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826001839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826001839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:18:19Z","timestamp":1781191099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826001839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0149291826001839"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.05.021","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancements in Prenatal Diagnosis and Potential Fetal Therapies for Spinal Muscular Atrophy","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}